KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Non-Current Assets: 2018-2024

Historic Non-Current Assets for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Dec 2024 value amounting to $104.0 million.

  • Aurinia Pharmaceuticals' Non-Current Assets fell 18.47% to $88.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.8 million, marking a year-over-year decrease of 18.47%. This contributed to the annual value of $104.0 million for FY2024, which is 15.59% down from last year.
  • Per Aurinia Pharmaceuticals' latest filing, its Non-Current Assets stood at $104.0 million for FY2024, which was down 15.59% from $123.3 million recorded in FY2023.
  • In the past 5 years, Aurinia Pharmaceuticals' Non-Current Assets ranged from a high of $123.3 million in FY2023 and a low of $28.3 million during FY2022.
  • For the 3-year period, Aurinia Pharmaceuticals' Non-Current Assets averaged around $85.2 million, with its median value being $104.0 million (2024).
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 382.69% in 2020, then crashed by 32.08% in 2021.
  • Over the past 5 years, Aurinia Pharmaceuticals' Non-Current Assets (Yearly) stood at $44.2 million in 2020, then plummeted by 32.08% to $30.0 million in 2021, then dropped by 5.73% to $28.3 million in 2022, then surged by 335.23% to $123.3 million in 2023, then declined by 15.59% to $104.0 million in 2024.